Figures computed from official regulatory filings — .
Analysttarget 63 USD (+34%) · consensus 4.2/5 · 3 buy · 2 hold · 0 sell
Ownershipinsiders 3.35% · institutions 89.13% · short 17.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for RIGEL PHARMACEUTICALS INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
37 buys276 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Schorno Dean L | Other | $44.1K | SEC |
| Schorno Dean L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schorno Dean L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Santos David A | Other | $41.5K | SEC |
| Schorno Dean L | Exercise | $8.8K | SEC |
| Schorno Dean L | Exercise | $31.1K | SEC |
| Schorno Dean L | Exercise | $11.6K | SEC |
| Schorno Dean L | Exercise | $48.4K | SEC |
| Schorno Dean L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schorno Dean L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Furey Raymond J. | Other | $41.7K | SEC |
| RODRIGUEZ RAUL R | Other | $115.1K | SEC |
| HANNAH ALISON L. | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ali-Jackson Kamil | Sell | $87.5K | SEC |
| Santos David A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Furey Raymond J. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rojkjaer Lisa | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RODRIGUEZ RAUL R | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schorno Dean L | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rojkjaer Lisa | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RODRIGUEZ RAUL R | Other | $72.4K | SEC |
| Schorno Dean L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Schorno Dean L | Exercise | $22.4K | SEC |
| Furey Raymond J. | Other | $26.2K | SEC |
| Schorno Dean L | Exercise | $27.7K | SEC |